Castany Sílvia, Carcolé Mireia, Leánez Sergi, Pol Olga
Grup de Neurofarmacologia Molecular, Institut d'Investigació Biomèdica Sant Pau & Institut de Neurociències, Universitat Autònoma de Barcelona, Barcelona, Spain.
PLoS One. 2016 Jan 5;11(1):e0146427. doi: 10.1371/journal.pone.0146427. eCollection 2016.
Painful diabetic neuropathy is a common complication of diabetes mellitus which is poorly controlled by conventional analgesics. This study investigates if treatment with an heme oxygenase 1 (HO-1) inducer, cobalt protoporphyrin IX (CoPP), could modulate the allodynia and hyperalgesia induced by diabetes and enhanced the antinociceptive effects of morphine. In a diabetic mice model induced by the injection of streptozotocin (STZ), we evaluated the antiallodynic and antihyperalgesic effects produced by the intraperitoneal administration of 5 and 10 mg/kg of CoPP at several days after its administration. The antinociceptive actions produced by the systemic administration of morphine alone or combined with CoPP were also evaluated. In addition, the effects of CoPP treatment on the expression of HO-1, the microglial activation marker (CD11b/c), the inducible nitric oxide synthase (NOS2) and μ-opioid receptors (MOR), were also assessed. Our results showed that the administration of 10 mg/kg of CoPP during 5 consecutive days completely blocked the mechanical and thermal hypersensitivity induced by diabetes. These effects are accompanied by the increased spinal cord, dorsal root ganglia and sciatic nerve protein levels of HO-1. In addition, the STZ-induced activation of microglia and overexpression of NOS2 in the spinal cord were inhibited by CoPP treatment. Furthermore, the antinociceptive effects of morphine were enhanced by CoPP treatment and reversed by the administration of an HO-1 inhibitor, tin protoporphyrin IX (SnPP). The spinal cord expression of MOR was also increased by CoPP treatment in diabetic mice. In conclusion, our data provide the first evidence that the induction of HO-1 attenuated STZ-induced painful diabetic neuropathy and enhanced the antinociceptive effects of morphine via inhibition of microglia activation and NOS2 overexpression as well as by increasing the spinal cord levels of MOR. This study proposes the administration of CoPP alone or combined with morphine as an interesting therapeutic approach for the treatment of painful diabetic neuropathy.
疼痛性糖尿病神经病变是糖尿病的一种常见并发症,常规镇痛药对其控制效果不佳。本研究调查了血红素加氧酶1(HO-1)诱导剂钴原卟啉IX(CoPP)治疗是否能调节糖尿病诱导的异常性疼痛和痛觉过敏,并增强吗啡的镇痛作用。在通过注射链脲佐菌素(STZ)诱导的糖尿病小鼠模型中,我们评估了在给予CoPP后数天腹腔注射5和10 mg/kg CoPP产生的抗异常性疼痛和抗痛觉过敏作用。还评估了单独全身给予吗啡或与CoPP联合给予吗啡产生的镇痛作用。此外,还评估了CoPP治疗对HO-1、小胶质细胞活化标志物(CD11b/c)、诱导型一氧化氮合酶(NOS2)和μ-阿片受体(MOR)表达的影响。我们的结果表明,连续5天给予10 mg/kg CoPP可完全阻断糖尿病诱导的机械性和热超敏反应。这些作用伴随着脊髓、背根神经节和坐骨神经中HO-1蛋白水平的升高。此外,CoPP治疗可抑制STZ诱导的脊髓小胶质细胞活化和NOS2的过度表达。此外,CoPP治疗可增强吗啡的镇痛作用,而给予HO-1抑制剂锡原卟啉IX(SnPP)可逆转该作用。CoPP治疗还可增加糖尿病小鼠脊髓中MOR的表达。总之,我们的数据首次证明,HO-1的诱导可减轻STZ诱导的疼痛性糖尿病神经病变,并通过抑制小胶质细胞活化和NOS2过度表达以及增加脊髓中MOR的水平来增强吗啡的镇痛作用。本研究提出单独给予CoPP或与吗啡联合给予CoPP作为治疗疼痛性糖尿病神经病变的一种有前景的治疗方法。